FDA Clearance Tracker · DEN170073
ContaCT
Last checked: Nov 19, 2026Latest source record: Feb 13, 2018 (this decision)Source: openFDAMethods & limitations
Decided
Feb 13, 2018
De Novo granted
Time to decision
137 days
Received Sep 29, 2017. Calendar days, including time FDA spent waiting on the applicant.
Pathway
De Novo
Direct
Device class
Class II
The decision
- FDA number
- DEN170073
- Device name
- ContaCT
- Applicant
- Viz.Al, Inc.
- Applicant location
- San Francisco, CA
- Received
- Sep 29, 2017
- Decided
- Feb 13, 2018
- Decision
- De Novo granted
- Submission type
- Direct
Device type
- Device class
- Class II
- Regulation
- 21 CFR 892.2080
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- FDA granted this as a De Novo request, which means it created a new device type. There was no existing device to compare it to.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for DEN170073
- Decision summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
Other decisions for Viz.Al, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
No other decisions since 2015 under this exact applicant name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.